HCW Biologics Inc.
HCWB
$7.05
-$0.58-7.60%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.57M | 3.50M | 3.92M | 3.93M | 2.84M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.57M | 3.50M | 3.92M | 3.93M | 2.84M |
| Cost of Revenue | 1.61M | 2.36M | 2.70M | 2.76M | 2.28M |
| Gross Profit | 959.40K | 1.13M | 1.22M | 1.16M | 560.30K |
| SG&A Expenses | 24.15M | 29.54M | 30.54M | 21.56M | 18.69M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.05M | 39.28M | 41.10M | 31.78M | 28.56M |
| Operating Income | -29.48M | -35.79M | -37.18M | -27.85M | -25.72M |
| Income Before Tax | -30.02M | -37.33M | -38.37M | -27.39M | -24.99M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -30.02 | -37.33 | -38.37 | -27.39 | -24.99 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.02M | -37.33M | -38.37M | -27.39M | -24.99M |
| EBIT | -29.48M | -35.79M | -37.18M | -27.85M | -25.72M |
| EBITDA | -28.30M | -35.01M | -36.25M | -26.77M | -24.58M |
| EPS Basic | -31.50 | -40.18 | -41.55 | -30.19 | -27.81 |
| Normalized Basic EPS | -19.60 | -24.25 | -25.11 | -18.87 | -17.46 |
| EPS Diluted | -31.50 | -40.18 | -41.55 | -30.19 | -27.81 |
| Normalized Diluted EPS | -19.60 | -24.25 | -25.11 | -18.87 | -17.46 |
| Average Basic Shares Outstanding | 3.88M | 3.72M | 3.67M | 3.63M | 3.59M |
| Average Diluted Shares Outstanding | 3.88M | 3.72M | 3.67M | 3.63M | 3.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |